Blue Buffalo faces class action over grain-free DCM claims: full analysis

A proposed class action filed in federal court in Illinois is challenging Blue Buffalo’s marketing of grain-free dog food, alleging the company sold those diets as healthy despite evidence tying some grain-free formulations to dilated cardiomyopathy in dogs. The suit was brought by a Lake County, Illinois, family that says its 10-year-old dog, Maya, developed DCM after eating Blue Buffalo Wilderness Chicken Grain-Free for years, and that the company failed to adequately warn pet parents about the risk. (petfoodindustry.com)

The filing revives one of the most contentious issues in companion animal nutrition. Concern around diet-associated DCM accelerated in July 2018, when the FDA said it had begun investigating reports of canine DCM in dogs eating certain diets, many labeled grain-free and containing high proportions of peas, lentils, other pulses, and/or potatoes. In a later public update, the agency said reported cases extended beyond breeds classically predisposed to DCM, helping shift the issue from a niche cardiology concern to a broader clinical and commercial debate. (fda.gov)

Blue Buffalo has been part of that conversation for years. General Mills completed its acquisition of Blue Buffalo on April 24, 2018, just months before the FDA’s first public alert on the DCM issue. In its 2019 update, the FDA published brand counts from reported cases; Blue Buffalo appeared among the brands most frequently named in reports, though the agency also stressed that those reports did not establish causation and that multiple factors could be involved. (investors.generalmills.com)

The scientific backdrop is still evolving. A 2018 JAVMA commentary by Lisa Freeman, Joshua Stern, and colleagues helped define the early veterinary response, arguing that diet-associated DCM was a real clinical concern and recommending that veterinarians take detailed diet histories, especially for dogs eating boutique, exotic-ingredient, or grain-free diets. Subsequent retrospective work documented differences between suspected diet-associated and primary DCM cases, and many cardiologists have reported improvement in some affected dogs after diet change and appropriate treatment. More recently, Freeman’s work on diet-associated DCM was recognized by the AKC Canine Health Foundation, underscoring that the issue remains active in academic cardiology and nutrition circles. (experts.illinois.edu)

That said, not everyone in the industry agrees on the strength of the evidence. A 2023 study publicized by BSM Partners and board-certified cardiologists reported no negative impact of grain-free diets on heart health in the dogs studied and said those diets did not lead to DCM in that trial. That doesn’t erase the FDA investigation or the clinical experience of referral cardiologists, but it does help explain why the issue remains contested in both courtrooms and exam rooms. (prnewswire.com)

Why it matters: For practicing veterinarians, this lawsuit is less about one company than about how nutrition risk is communicated. Pet parents are likely to come in with headlines, legal claims, and strong feelings about grain-free foods, but the clinical conversation still needs nuance. The most defensible approach remains to take a thorough diet history, ask specifically about grain-free and pulse-heavy products, evaluate dogs with murmurs, arrhythmias, syncope, exercise intolerance, or CHF signs promptly, and be ready to discuss why evidence of association can matter clinically even when causation is still being debated. (medvet.com)

The case also touches a broader industry pressure point: marketing. If plaintiffs can persuade the court that “healthy” or similar claims were misleading in the context of long-running DCM concerns, manufacturers across the category may face sharper scrutiny of how they position grain-free and specialty diets. That could matter not only for litigation exposure, but also for formulation strategy, label language, and veterinarian-facing education. This is particularly relevant in a market where Blue Buffalo remains a major brand under General Mills and where pet parents increasingly expect both premium positioning and scientific substantiation. (petfoodindustry.com)

What to watch: The next signals will be Blue Buffalo’s formal court response, whether the plaintiffs can win class certification, and whether the case uncovers internal marketing or safety documents through discovery. Beyond the lawsuit itself, veterinarians should watch for any new FDA communication, additional peer-reviewed work on diet-associated DCM mechanisms, and whether major brands adjust messaging around grain-free formulations. (petfoodindustry.com)